Today on The Tape Reader: The Federal Reserve's hawkish pivot under its new chair accelerates a rotation out of tech, while the memory chip sector lands a wave of massive analyst upgrades ahead of next week's critical earnings.
As anticipated heading into his debut meeting, Fed Chair Kevin Warsh delivered a decisively hawkish pivot on Wednesday. While holding rates at 3.50-3.75% as expected, the new dot plot revealed nearly half of policymakers anticipate a rate hike in 2026, pushing the median end-of-year target to 3.8% from March's 3.4%. Warsh also officially ended traditional forward guidance and established five new monetary policy task forces, shifting to a strictly data-dependent stance that triggered a sharp sell-off in risk assets.
Why it matters
Warsh's decision to abolish forward guidance marks the regime shift we've been tracking since the hawkish 8-4 split in the April minutes. Every major data print is now a live event for Fed policy, injecting significant intraday volatility and reinforcing the 'higher-for-longer' environment that heavily favors cyclical sectors over long-duration growth.
Building on the pre-earnings momentum we've been tracking, Micron (MU) shares surged Wednesday after a wave of Tier-1 upgrades validated a structural AI memory supercycle. Deutsche Bank's Melissa Weathers led the pack, raising her target to $1,500 from $1,000 based on a supply-demand imbalance extending into 2028. Citi and RBC also boosted their targets to $1,200, brushing off recent tech-sector volatility ahead of the company's critical June 24 earnings print.
Why it matters
This concentrated wave of aggressive price target hikes provides the institutional conviction needed to counter the recent semiconductor deleveraging we noted earlier this week. It firmly positions Micron's upcoming earnings as a structural read-through for the entire AI infrastructure buildout.
Following up on the initial upgrade we covered last week, Citi has reiterated its Buy rating and $575 price target on AMD. The note leans heavily into the record Meta GPU deal and the recent acquisition of memory startup MEXT, positioning AMD to capitalize on 'agentic AI' demand and solidifying its role as Nvidia's primary competitor.
Why it matters
Citi's reiteration keeps the spotlight on AMD's fundamental story change. Amidst the broader semiconductor sell-off, consistent Tier-1 support for AMD's AI infrastructure pivot offers a relative strength play for momentum traders.
Bernstein SocGen Group raised its price target on Delta Air Lines (DAL) to $93 from $88 on Wednesday, maintaining an Outperform rating. The firm's analyst cited expectations that Delta will beat Q2 estimates by at least 2%, driven by robust travel demand and improved cost efficiencies from higher completion factors.
Why it matters
This upgrade from a respected desk serves as a potential catalyst for DAL. The thesis of strong demand and better cost control points to a positive fundamental story change. For traders, this action can put the stock in play, potentially triggering a breakout from its recent consolidation as institutions may follow the new, more bullish target.
La-Z-Boy (LZB) shares surged more than 16% after the market close on Wednesday, gapping up on a significant earnings beat. The furniture retailer reported Q4 adjusted EPS of $1.26, crushing the consensus estimate of $0.82. The company also announced a new $300 million share repurchase authorization and provided Q1 guidance that met or exceeded expectations, signaling confidence despite a soft industry backdrop.
Why it matters
This is a classic earnings-driven episodic pivot. The combination of a massive EPS surprise, a substantial buyback program, and solid guidance provides a trifecta of bullish catalysts. For traders, this creates an actionable gap-up scenario, with the potential for continuation driven by institutional accumulation. The key is to watch if the stock can hold its gap and build a new base at these higher levels.
Intellia Therapeutics (NTLA) shares climbed over 10% on Wednesday after the company announced positive additional data from the Phase 3 HAELO trial for lonvo-z, its in-vivo CRISPR-based therapy for hereditary angioedema. The results, showing robust and sustained reductions in attack rates, were published in the New England Journal of Medicine, adding significant scientific validation. The company is proceeding with a rolling BLA submission, targeting a launch in the first half of 2027.
Why it matters
This is a significant de-risking event for Intellia's lead asset and a major validation for the entire in-vivo CRISPR editing platform. Strong Phase 3 data published in a top-tier journal provides a powerful catalyst that can attract institutional interest. For traders, this provides a clear fundamental story change supporting the stock's upward momentum, creating a setup for a potential breakout and sustained run as it moves closer to commercialization.
Shares of uniQure (QURE) exploded over 78% on Wednesday after the FDA reversed its previous stance, indicating the company's gene therapy for Huntington's disease, AMT-130, could qualify for accelerated approval. The agency's shift, detailed in new draft guidance for gene therapies, allows for a Biologics License Application (BLA) filing based on existing Phase 1/2 data. UniQure now plans to file the BLA in the third quarter of 2026.
Why it matters
This is a major de-risking event and a textbook episodic pivot for QURE. The FDA's U-turn dramatically shortens the timeline to potential commercialization, creating a powerful catalyst that transformed the stock's trajectory overnight. For traders, this highlights the explosive potential of binary biotech events and signals a potentially more flexible FDA stance on rare disease therapies, which could create tailwinds for other companies in the gene therapy space.
The 9.7% rally Moderna (MRNA) enjoyed yesterday on a favorable initial FDA staff review is facing a reality check ahead of today's advisory committee vote. A closer reading of the briefing documents reveals FDA scientists flagged critical data gaps in the mFlusiva mRNA flu vaccine, specifically citing missing performance metrics across different flu strains and in high-risk subgroups.
Why it matters
This sharply alters the setup we tracked yesterday. What looked like a cleanly de-risked catalyst is now a highly volatile binary event, with the newly surfaced data gaps creating significant downside risk if the AdCom recommendation turns negative.
The sector rotation out of tech we saw following Lombard Odier's recent downgrade has accelerated in the wake of the Fed's hawkish pivot. Relative Rotation Graphs (RRG) confirm institutional capital is actively flowing out of the weakening Technology (XLK) sector and into Financials (XLF), Industrials (XLI), and Materials (XLB)—propelling the Dow to a record high even as the Nasdaq sold off.
Why it matters
This cements the shift from a one-day tech profit-taking event into a durable change in market leadership. With the Fed signaling a 'higher-for-longer' rate environment, the market is structurally rewarding cyclical value over the crowded semiconductor trades that dominated the first half of the year.
After ES futures gapped up 100 points to the 7,500 resistance level on the US-Iran de-escalation news we tracked yesterday, the technical setup has fractured under the weight of the hawkish Fed. Market profile analysis from the post-FOMC session shows sellers seizing control, while 0DTE options flow reveals extreme bearish concentration at the SPY 730 strike—creating a heavy downward pull if the 743.47 support breaks.
Why it matters
The intraday battle lines are drawn between geopolitical relief and monetary tightening. If the market fails to defend the gap-up from the Iran news, the heavy options gravity at 730 could accelerate a rapid cascade lower.
SpaceX's (SPCX) parabolic post-IPO surge continues to defy gravity, with the stock briefly touching a $3 trillion valuation after hitting $225—a 67% gain from its $135 offering price. The manic price action remains driven by the extreme supply/demand imbalance of a 4% float and forced passive ETF buying, completely detaching from fundamentals like Morningstar's fair value estimate and a projected $4.9B net loss in 2025.
Why it matters
As the $2.5T valuation we noted yesterday pushes toward $3T, SPCX is cementing its status as a structural anomaly. The combination of retail FOMO and institutional forced-buying creates an explosive but deeply unstable dynamic, setting up a prime exhaustion short once the buying pressure abates.
Shares of Rackspace Technology (RXT) have surged over 540% in 2026, building on the momentum from a new multi-year agreement with AMD to provide secure AI infrastructure. This turnaround story has propelled the stock from deep lows to over $6. The move represents a significant breakout for the company as it pivots into the high-demand AI infrastructure space.
Why it matters
RXT's massive run exemplifies a powerful momentum breakout driven by a fundamental business pivot. The partnership with a major player like AMD validates its new strategy and has forced a complete re-rating of the stock. For momentum traders, this is a case study in tracking names with a true story change, offering opportunities for continuation plays as long as it holds key technical levels and the AI narrative remains strong.
Fed's Hawkish Pivot Under New Chair New Fed Chair Kevin Warsh's debut saw him hold rates but signal a potential hike by year-end, with the dot plot shifting higher and forward guidance eliminated. This triggered a sell-off in equities, a rise in yields, and a stronger dollar.
Analyst Conviction in AI Memory Supercycle Multiple tier-1 analysts (Deutsche Bank, Citi, RBC, Cantor) issued major price target hikes for Micron, citing a structural supply-demand imbalance for memory driven by AI that could last into 2028. This contrasts with broader tech weakness and reinforces the 'picks and shovels' thesis.
Biotech Catalyst Day Several biotech names are moving on specific catalysts. UniQure (QURE) surged after the FDA cleared a path for accelerated approval for its Huntington's gene therapy, while Intellia (NTLA) gained on positive Phase 3 data for its CRISPR treatment. Moderna (MRNA) faces a key FDA meeting for its flu shot.
Clear Sector Rotation Markets are exhibiting a clear rotation out of crowded tech and semiconductor names into value and cyclicals like financials and industrials. This shift is driven by the Fed's hawkish tone and profit-taking in high-beta names.
Parabolic Moves and Valuation Strains SpaceX continues its post-IPO parabolic run, trading like a meme stock with a valuation completely detached from fundamentals. Meanwhile, other parabolic names like SanDisk and Corning are showing signs of exhaustion and are facing valuation pressure and analyst downgrades.
What to Expect
2026-06-18—FDA VRBPAC meeting for Moderna's (MRNA) mFlusiva flu vaccine.
2026-06-24—Micron (MU) is scheduled to report earnings, a key test for the memory sector.
2026-09-01—Potential for first Fed rate hike since the pause, as per Citadel's forecast.
2026-09-30—End of Q3 2026, when UniQure (QURE) plans to file its Biologics License Application (BLA).
2027-01-01—First half of 2027, expected launch window for Intellia's (NTLA) lonvo-z treatment.
How We Built This Briefing
Every story, researched.
Every story verified across multiple sources before publication.
🔍
Scanned
Across multiple search engines and news databases
634
📖
Read in full
Every article opened, read, and evaluated
194
⭐
Published today
Ranked by importance and verified across sources
12
— The Tape Reader
🎙 Listen as a podcast
Subscribe in your favorite podcast app to get each new briefing delivered automatically as audio.
Apple Podcasts
Library tab → ••• menu → Follow a Show by URL → paste